

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of 9-(2-Deoxy-2-Fukuoro- β -D- Abinoruransyl)Hypoxhine. The First Direct Introduction of A 2'- β -Fldoro Substituent in Ppepormed Purine Nucleosides. Studies Directed Toward the Synthesis of 2'-DEOXY-2'-Substituted Arabppmocebosides. 8.¹

Jacek Krzeminski^a; Barbara Nawrot^a; Krzysztof W. Pankiewicz^a; Kyoichi A. Watanabe^a

^a Laboratory of organic chemistry, sloan-Kettering Institute for Cancer Research, Sloan-Kettering Division of Graduate School of Medical. Sciences, Cornell University, New York, NY

To cite this Article Krzeminski, Jacek , Nawrot, Barbara , Pankiewicz, Krzysztof W. and Watanabe, Kyoichi A.(1991) 'Synthesis of 9-(2-Deoxy-2-Fukuoro- β -D- Abinoruransyl)Hypoxhine. The First Direct Introduction of A 2'- β -Fldoro Substituent in Ppepormed Purine Nucleosides. Studies Directed Toward the Synthesis of 2'-DEOXY-2'-Substituted Arabppmocebosides. 8.', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 4, 781 — 798

To link to this Article: DOI: 10.1080/07328319108046662

URL: <http://dx.doi.org/10.1080/07328319108046662>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHESIS OF 9-(2-DEOXY-2-FLUORO- β -D-ARABINOFURANOSYL)HYPOXANTHINE.
THE FIRST DIRECT INTRODUCTION OF A 2'- β -FLUORO SUBSTITUENT IN
PREFORMED PURINE NUCLEOSIDES. STUDIES DIRECTED TOWARD
THE SYNTHESIS OF 2'-DEOXY-2'-SUBSTITUTED ARABINONUCLEOSIDES. 8.¹**

Jacek Krzeminski, Barbara Nawrot, Krzysztof W. Pankiewicz*
and Kyoichi A. Watanabe

Laboratory of Organic Chemistry, Sloan-Kettering Institute
for Cancer Research, Sloan-Kettering Division of Graduate School
of Medical Sciences, Cornell University, New York, NY 10021.


Abstract. The 3',5'-di-O-acetyl-, 3',5'-di-O-benzyl-, 3'-O-acetyl-5'-O-trityl- and 3',5'-di-O-trityl-2'-O-triflyl-1-benzylinosine (**8c**, **15**, **20c**, and **27**, respectively) were prepared and subjected to nucleophilic reaction with TASF. Thus, 3',5'-O-(1,1,3,3-tetraisopropylidisiloxanyl)-1-benzylinosine (**5c**) was triflylated, desilylated, and then acetylated to give **8c**. Also, **5c** was converted into the 2'-O-tetrahydropyranyl (THP) derivative **11** which was desilylated and then benzylated to give 2'-O-tetrahydropyranyl-O^{3'},O^{5'},N¹-tribenzylinosine (**13**). Removal of the THP group from **13** followed by triflylation afforded 2'-O-triflyl-O^{3'},O^{5'},N¹-tribenzylinosine (**15**). 3'-O-Acetyl-2'-O-triflyl-5'-O-trityl-1-benzylinosine (**20**) was prepared from 5'-O-trityl-1-benzylinosine (**18c**) by conversion into the 2',3'-O-(di-n-butylstannylene) derivative which was treated with triflyl chloride and then acetylated. Treatment of 1-benzylinosine (**4c**) with trityl chloride in pyridine containing p-dimethylaminopyridine afforded a mixture of 2',5'- and 3',5'-di-O-trityl-1-benzylinosine (**25** and **26**, respectively). These regioisomers were chromatographically separated. Triflylation of **26** gave 2'-O-triflyl-3',5'-di-O-trityl-1-benzylinosine (**27**).

The triflates **8c** and **15** only afforded elimination products upon treatment with TASF. However, the triflate group in **20c** and **27** was displaced by fluoride with formation of the 2'-fluoro-arabino nucleosides, **21c** and **28**, in 10 and 30% yield, respectively. After deprotection of **28**, 9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)hypoxanthine (**1**, F-ara-H) was obtained in good yield. The conformational influence of the sugar protecting groups on the rate of nucleophilic substitution against elimination is discussed.

The synthesis of several 9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-9H-purines has recently been reported from our laboratory.² Some of these nucleosides exhibit interesting biological activity. For example, the hypoxanthine nucleoside **1** (F-ara-H, Figure 1) showed potent inhibitory

activity against the growth of *Leishmania tropica* promastigotes,³ and the guanine nucleoside (2, F-ara-G) was found to be selectively toxic to T-cells.^{2,4,5} The 2'-fluoro-arabinosylpurines in these studies were prepared by condensation of 3-O-acetyl-5-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide⁶ with N⁶-benzoyladenine, 6-chloropurine,

Figure 1




2,6-dichloropurine, or 2-acetamido-6-chloropurine, followed by appropriate functional group replacement and deprotection. The overall yield was generally very low. For example, F-ara-H (1) was prepared by deamination of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine (3, F-ara-A), but the overall yield from the bromo sugar was only 7%.

We have recently developed⁷ a method of synthesis of 5-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-1-methyluracil by direct displacement of the 2'-triflate group in 4,5'-anhydro-2'-O-triflyl-1-methylpseudouridine by fluorine on treatment with tris(dimethylamino)sulfur (trimethylsilyl)-difluoride (TASF).

In the purine series, several 9-(2-deoxy-2-substituted-β-D-arabinofuranosyl)adenine derivatives (except F-ara-A) have been prepared⁸ by direct displacement of the 2'-triflate group of the adenosine derivative with nucleophiles. We prepared 3',5'-di-O-acetyl-2'-O-triflyl derivatives of adenosine, inosine, and 1-benzylinosine (8a, 8b and 8c) by the procedure shown in Scheme 1.

Treatment of adenosine 2'-triflate (8a) with KF/DMF, Amberlyst A26 (F⁻) in acetonitrile, or TASF in methylene chloride always resulted in the formation of a mixture of adenine and 9-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)adenine (10a). No fluorinated nucleoside was detected. Compound 10a was isolated in yield of 40% in the reaction with KF/DMF.

Apparently, some **8a** decomposed during the reaction, releasing acetate ion which displaced the triflate group, giving rise to **10a** (Scheme 2). The




a Series: B = adenine, b Series: B = hypoxanthine, c Series: B = 1-benzylhypoxanthine

Scheme 1

triflates, **8b** and **8c**, when treated with TASF, also afforded a mixture of the corresponding purine base and peracetylated arabino nucleosides. We made a similar observation⁷ when 4,5'-anhydro-3'-O-acetyl-2'-O-triflyl-1-methylpseudouridine was treated with CsF/DMF or Amberlyst A26/CH₂Cl₂.

In order to avoid the problems caused by acetate displacement of triflate, we synthesized 3',5'-di-O-benzyl-2'-O-triflyl-1-benzylinosine




Scheme 2

(**15**). Thus, 3',5'-O-(1,1,3,3-tetraisopropyl)disiloxanyl-1-benzylinosine (**5c**, Scheme 3) was treated with dihydropyran (DHP)/TsOH, and then desilylated with Et₃NHF/THF to obtain **12**. Benzylation of **12** followed by 2'-deprotection and triflylation afforded **13-15**. Contrary to our expectation, treatment of **15** with TASF only afforded the elimination products **16** and **17**, and no trace of F-ara-H was detected in the reaction mixture.


Facile elimination of trifluoromethanesulfonic acid from **15** with the formation of the olefin **16** is probably due to the fact that the sugar has the C₃, *endo* conformation, in which the triflate group on C₂, and the hydrogen on C₃, are almost in a trans di-*axial* configuration. Ikehara *et*

al. reported⁹ that the amount of C₃, endo conformer in 2'-substituted adenosines increases linearly with the electronegativity of the 2'-substituent. Thus, the presence of the electronegative 2'-triflate group may force **15** to assume the C₃, endo conformation, which favors elimination.




Scheme 3

The furanose ring conformation may be altered by using different protecting groups at C5' and C3' of the purine nucleoside 2'-triflate. It has been suggested that bulky trityl groups may force the furanose ring to assume an unfavorable conformation^{10,11} for trans elimination. We therefore synthesized 5'-O-trityl-3'-O-acetyl-2'-O-triflyl nucleosides **20** (Scheme 4) from 5'-O-trityl-adenosine¹² (**18a**), -inosine¹³ (**18b**), and -1-benzylinosine (**18c**). Treatment of compounds **18** with Bu₂SnO/MeOH followed by CF₃SO₂Cl yielded the corresponding 2'-O-triflates **19**, which, without isolation, were acetylated to **20**. Treatment of **20a** and **20c** with TASf in CH₂Cl₂ afforded the desired protected F-ara-A and F-ara-H (**21a** and **21c**) in 4% and 10% yield, respectively. The reaction of **20b** with TASf, however, gave an unseparable mixture of the sugar fluorinated product **21b** and 2',3'-di-O-acetylated derivative **22b** along with the furan derivatives **23** and **24** and hypoxanthine. It has been recently reported¹⁴ that treatment of 5'-O-tritylcordycepin with diethylamino sulfur trifluoride (DAST) followed by detritylation afforded 9-(2-fluoro-2,3-dideoxy-β-D-threo-pentofuranosyl)-adenine in 10% yield. According to authors comment this fluorination was



Scheme 4



Scheme 5

facilitated by the absence of an oxygen function on the adjacent 3'-carbon atom.

Detailed examination of the reaction of triflates **20** with TASF revealed depurination to be the major course of the reaction. Displacement of the triflate group by acetate also occurs to give 9-(2,3-di-O-acetyl-5-O-trityl- β -D-arabinofuranosyl)purines (**22**, path A, Scheme 4). Although nucleophilic displacement of the triflate group with fluoride ion takes place to some extent, a facile double elimination of triflate and the purine base (path B) affords the furan derivatives **23** and **24**. Compound **24** was converted into **23** by acetylation. Similar triflate elimination from carbohydrates in the presence of fluoride ion is known.^{15,16} The above

data appear to support our concept that the C₃,-endo to C₂,-endo conformational change prevents triflate elimination so that nucleophilic displacement of 2'-triflate by fluoride nucleophile becomes possible. In order to further promote conformational shift toward C₂,-endo and prevent formation of acetate ion during the reaction, we prepared 3',5'-di-O-trityl-2'-O-triflyl-1-benzylinosine (**27**). The relatively large J_{1,2'} value of 7.1 Hz (in CHCl₃) for the 3',5'-di-O-trityl derivative **27** versus small 1',2' coupling (2.5 - 4.1 Hz) in **8**, **15** and **20** indicates that trityl groups did cause the desired conformational change in **27** toward C₂,-endo. When **27** was treated with TASF, the yield of the desired 2'-fluorinated arabinonucleoside **28** was increased to 30%.

Detritylation of **28** with CF₃CO₂H/CHCl₃¹⁷ followed by hydrogenolysis afforded a good yield of F-ara-H (**1**, Scheme 5).

Studies directed toward the synthesis of other 2'-fluoro-arabinosylpurines are in progress.

Experimental Section

Melting points were determined on a Thomas-Hoover capillary apparatus and are uncorrected. Column chromatography was performed on silica gel G60 (70-230 mesh, ASTM, Merck). TLC was performed on Analtech Uniplates with short-wavelength UV light for visualization. Elementary analyses were performed by M-H-W Laboratories, Phoenix, AZ. ¹H and ¹⁹F NMR spectra were recorded on a JEOL FX90Q spectrometer with Me₄Si and CFCl₃ as the internal standards. Chemical shifts are reported in ppm (δ), and signals are described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet) and dd (double doublet). Values given for coupling constants are first order.

1-Benzylinosine (4c). To a suspension of inosine (**4b**, 10.7 g, 40 mmol) in DMF (400 mL) and DBU (8.96 mL, 60 mmol) was added benzyl bromide (7.13 mL, 60 mmol), and the mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo, and the residue was crystallized from EtOH (200 mL) to obtain **4c** (13.5 g, 94%), mp 220-222 °C (lit.¹⁸ mp 219-222 °C).

3',5'-O-(1,1,3,3-Tetraisopropylidisiloxan-1,3-yl)-1-benzylinosine (5c).

A mixture of **4c** (9.9 g, 27.6 mmol) and 1,3-dichloro-1,1,3,3-tetraisopropylidisiloxane (10.0 g, 31.7 mmol) in pyridine (100 mL) was stirred at room temperature overnight. The pyridine was removed in vacuo, and the residue partitioned between CHCl_3 (300 mL) and H_2O (50 mL). The organic layer was washed with H_2O (2 x 50 mL), dried (Na_2SO_4), and concentrated in vacuo. The residue was chromatographed on silica gel ($\text{CHCl}_3/\text{EtOH}$, 40:1 v/v) to obtain **5c** (13.2 g, 81%). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 0.94–1.02 (28H, m, i-Pr), 3.95–4.02 (3H, m, $\text{H}4',5',5''$), 4.49–4.54 (2H, m, $\text{H}2',3'$), 5.25 (2H, s, CH_2Ph), 5.67 (1H, d, $2'\text{-OH}$, exchangeable), 5.85 (1H, s, $\text{H}1'$), 7.32 (5H, s, CH_2Ph), 8.19, 8.52 (two 1H singlets, H2 and H8). Anal. Calcd for $\text{C}_{29}\text{H}_{44}\text{N}_4\text{O}_6\text{Si}_2$: C, 59.76; H, 7.38; N, 9.32. Found: C, 60.05; H, 7.38; N, 9.15.

2'-O-Triflyladosine (7a). To a mixture of **5a**¹⁹ (500 mg, 1.0 mmol), DMAP (120 mg, 1.0 mmol) and Et_3N (240 μL , 2.0 mmol) in CH_2Cl_2 (10 mL) was added $\text{CF}_3\text{SO}_2\text{Cl}$ (212 μL , 2.0 mmol), and the mixture was stirred at room temperature for 0.5 h. After concentration of the mixture in vacuo, the residue was dissolved in 1 N Et_3NHF in THF (3 mL). The mixture was kept overnight at room temperature, and then concentrated in vacuo. The residue was chromatographed on silica gel ($\text{CHCl}_3/\text{EtOH}$, 9:1 v/v) to obtain **7a** (300 mg, 75%) as a foam. ^1H NMR ($\text{Me}_2\text{DO}-d_6$) δ 3.66–3.88 (2H, m, $\text{H}5',5''$), 4.02–4.13 (1H, m, $\text{H}4'$), 4.48–4.64 (1H, m, $\text{H}3'$, became dd at 4.61 on addition of D_2O , $J_{2',3'} = 5.0$, $J_{3',4'} = 5.5$ Hz), 5.89 (1H, dd, $\text{H}2'$, $J_{1',2'} = 4.4$, $J_{2',3'} = 5.0$ Hz), 6.40 (1H, d, $\text{H}1'$, $J_{1',2'} = 4.4$ Hz), 7.61 (2H, bs, NH_2), 8.20, 8.42 (two 1H singlets, H2, H8). This compound was too unstable for combustion analyses.

2'-O-Triflylinosine (7b). A mixture of **4b** (268 mg, 1 mmol) and $\text{Bu}_2\text{SnO}^{20}$ (249 mg, 1 mmol) in MeOH (50 mL) was heated under reflux until a clear solution was obtained, and then concentrated in vacuo. The residue was dissolved in DMF (15 mL), and treated with $\text{CF}_3\text{SO}_2\text{Cl}$ (185 mg, 1.1 mmol) at room temperature for 1 h. The mixture was concentrated in vacuo, and the residue chromatographed on silica gel ($\text{CHCl}_3/\text{EtOH}$, 9:1 v/v) as the eluent to obtain **7b** (148 mg, 37%) as a foam. ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.64–3.74 (2H, m, $\text{H}5',5''$), 3.99–4.08 (1H, m, $\text{H}4'$), 4.59 (1H, dd, $\text{H}3'$, $J_{2',3'} = 4.4$, $J_{3',4'} = 5.5$ Hz), 5.77 (1H, dd, $\text{H}2'$, $J_{1',2'} = 4.1$, $J_{2',3'} = 4.4$ Hz), 6.38 (1H,

d, H1', $J_{1,2'} = 4.1$ Hz), 8.12 (1H, d, H2, collapsed to a singlet upon addition of D₂O), 8.37 (1H, s, H8), 12.40 (1H, bs, NH). This compound decomposed in the mail sent for combustion analyses.

1-Benzyl-2'-O-triflylinosine (7c). In a similar manner to the conversion of 5a into 7a, 1-benzylinosine (5c, 584 mg, 1 mmol) was converted into 7c (295 mg, 60%) after chromatographic purification (CHCl₃/EtOH, 40:1 v/v) and crystallization from EtOH; mp 143–145 °C (dec). ¹H NMR (Me₂SO-d₆) δ 3.65–3.67 (2H, m, H5',5''), 3.99–4.06 (1H, m, H4'), 4.54–4.67 (1H, m, H3'), 5.24 (2H, s, CH₂Ph), 5.80 (1H, t, H2', $J_{1,2'} = J_{2,3'} = 3.6$ Hz), 6.39 (1H, d, H1', $J_{1,2'} = 3.6$ Hz), 7.35 (5H, s, CH₂Ph), 8.40, 8.67 (two 1H singlets for H2 and H8). Anal. Calcd for C₁₈H₁₇F₃N₄O₇S: C, 44.08; H, 3.50; N, 11.42; S, 6.54. Found: C, 44.32; H, 3.91; N, 11.23; S, 6.52.

3',5'-Di-O-acetyl-2'-O-triflyladenine (8a). A mixture of 7a (399 mg, 1.0 mmol) and Ac₂O (0.8 mL, 10 equiv.) in pyridine (10 mL) was left standing for 4 h, and then concentrated in vacuo. The residue was dried by azeotropic distillation of toluene (2 x 10 mL) and EtOH (2 x 10 mL) to obtain quantitative yield of 8a as a foam. ¹H NMR (Me₂SO-d₆) δ 1.98 (3H, s, Ac), 2.16 (3H, s, Ac), 4.11–4.51 (3H, m, H4',5',5''), 5.87 (1H, t, H-3', $J_{2,3'} = J_{3,4'} = 5.9$ Hz), 6.35 (1H, dd, H-2', $J_{1,2'} = 4.1$, $J_{2,3'} = 5.9$ Hz), 6.53 (1H, d, H-1', $J_{1,2'} = 4.1$ Hz), 7.44 (2H, bs, NH₂), 8.18, 8.57 (two 1H singlets, H2 and H8).

3',5'-Di-O-acetyl-2'-O-triflylinosine (8b) and 3',5'-di-O-acetyl-2'-O-triflyl-1-benzylinosine (8c). These compounds were prepared similarly.

8b: ¹H NMR (Me₂SO-d₆) δ 2.01 (3H, s, Ac), 2.16 (3H, s, Ac), 4.13–4.54 (3H, m, H4',5',5''), 5.78 (1H, dd, H3', $J_{2,3'} = 5.6$, $J_{3,4'} = 6.0$ Hz), 6.21 (1H, dd, H2', $J_{1,2'} = 4.1$, $J_{2,3'} = 5.6$ Hz), 6.54 (1H, d, H1', $J_{1,2'} = 4.0$ Hz), 8.13 (1H, d, H2, collapsed to a singlet upon addition of D₂O), 8.34 (1H, s, H8), 12.10 (bs, NH). **8c:** ¹H NMR (Me₂SO-d₆) δ 1.98 (3H, s, Ac), 2.15 (3H, s, Ac), 4.19–4.53 (3H, m, H4',5',5''), 5.24 (2H, s, CH₂Ph), 5.84 (1H, dd, H3', $J_{2,3'} = 5.8$, $J_{3,4'} = 6.0$ Hz), 6.21 (1H, dd, $J_{1,2'} = 4.0$, $J_{2,3'} = 5.8$ Hz), 6.57 (1H, d, H1', $J_{1,2'} = 4.0$ Hz), 7.53 (5H, s, CH₂Ph), 8.34, 8.68 (two 1H singlets, H2, H8).

Compounds 8a – 8c decomposed before combustion analyses.

9-(2,3,5-Tri-O-acetyl- β -D-arabinofuranosyl)adenine (10a). A mixture of **8a** (50 mg, 0.1 mmol) and NaOAc (10 mg) in DMF (2 mL) was stirred at room temperature overnight, and then concentrated in vacuo. The residue was chromatographed on silica gel (CHCl₃-EtOH 19:1 v/v) to obtain **10a** (22 mg), mp 142 °C (EtOH). (Lit.²¹ mp 142 °C.)

Reaction of 8a with KF/DMF, Amberlyst A-26 (F⁻)/MeCN, and TASF/CH₂Cl₂. Formation of (10a). (a). A mixture of **8a** (50 mg, 0.1 mmol) and KF (10 mg) in DMF (1 mL) was stirred at room temperature for 3 days, and then concentrated in vacuo. The residue was partitioned between CHCl₃ (20 mL) and H₂O (5 mL). The organic layer was separated, dried (MgSO₄), concentrated, and the residue chromatographed on silica gel column CHCl₃/EtOH (19:1 v/v) as the eluent. Unreacted **8a** (5 mg) was eluted first, followed by **10a** (17 mg, 41%). This sample was identical with **10a** prepared above.

(b). A mixture of **8a** (50 mg) and Amberlyst A-26 (F⁻) (150 mg) in CH₂Cl₂ (2 mL) was heated under reflux for 10 h. After cooling, the resin was removed by filtration, the filtrate concentrated in vacuo, and the residue chromatographed (CHCl₃/EtOH, 19:1 v/v) to give **10a** (17 %).

(c). To a cold (-70 °C) and stirred solution of **8a** (52 mg, 0.1 mmol) in dry CH₂Cl₂ (1 mL) was added a solution of TASF (90 mg, 0.3 mmol) in CH₂Cl₂ (0.6 mL) under argon. The mixture was allowed to warm to room temperature and stirring was continued for 24 h. An additional amount of TASF (90 mg) was added, and the mixture was stirred for another 24 h. The reaction was quenched by addition of H₂O (1 mL). The organic layer was separated, washed with H₂O (0.5 mL), dried (MgSO₄), concentrated in vacuo, and the residue chromatographed on silica gel (CHCl₃/EtOH, 19:1 v/v) to obtain **10a** (4 mg) and adenine (7 mg).

2'-O-(Tetrahydropyran-2-yl)-1-benzylinosine (12). A mixture of **5c** (9.0 g, 15.4 mmol), DHP (2.8 mL, 31.0 mmol), and TsOH (2.85 mg, 15 mmol) in CH₂Cl₂ (50 mL) was stirred overnight at room temperature. An additional amount of DHP (1 mL) was added, and the mixture was stirred at room temperature for 24 h, and then neutralized with satd. NaHCO₃ (50 mL). The organic layer was separated, washed (satd. NaHCO₃), dried (Na₂SO₄), and concentrated in vacuo. The residue (crude **11**, 10.0 g, 87%) was dissolved in 1M Et₃NHF in THF (40 mL), and the solution was kept at room temperature

for 24 h. Excess Et_3NHF was decomposed by addition of satd. NaHCO_3 . The mixture was concentrated in vacuo, and the residue was dried by repeated coevaporation with pyridine. Finally, the residue was suspended in pyridine, insoluble inorganic salts were removed by filtration, and the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel ($\text{CHCl}_3/\text{EtOH}$, 19:1 v/v) to give **12** (6.67 g, 98%) as a diastereomeric mixture.

Analytical samples of pure diastereomers were obtained by rechromatography of **12** (500 mg) using the same solvent system. The less polar isomer of **12** was obtained as a foam. ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.45–1.75 (6H, m, THP), 3.18–3.20 (2H, m, THP), 3.55–3.60 (2H, m, $\text{H}5',5''$), 3.95–4.00 (1H, m, $\text{H}4'$), 4.23 (1H, m, $\text{H}3'$), 4.57–4.69 (1H, m, THP), 5.07–5.22 (2H, m, 2 x OH), 5.22 (2H, s, CH_2Ph), 6.02 (1H, d, $\text{H}1'$, $J_{1',2'} = 5.8$ Hz), 7.32 (5H, s, CH_2Ph), 8.40, 8.63 (two 1H singlets, $\text{H}2$, $\text{H}8$). Anal. Calcd for $\text{C}_{22}\text{H}_{26}\text{N}_4\text{O}_6$: C, 59.97; H, 5.92; N, 12.16. Found: C, 59.95; H, 6.07; N, 12.40.

The more polar isomer of **12** was also obtained as a foam. ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.32–1.54 (6H, m, THP), 3.06–3.10 (2H, m, THP), 3.55–3.61 (2H, m, $\text{H}5',5''$), 3.98–4.01 (1H, m, $\text{H}4'$), 4.28–4.31 (1H, m, $\text{H}3'$), 4.60–4.72 (1H, m, THP), 5.04–5.30 (2H, m, 2 x OH), 5.23 (2H, s, CH_2Ph), 6.04 (1H, d, $\text{H}1'$, $J_{1',2'} = 6.3$ Hz), 7.31 (5H, s, CH_2Ph), 8.37, 8.63 (two 1H singlets, $\text{H}2$, $\text{H}8$). Anal. Found: C, 60.15; H, 6.10; N, 12.38.

3',5'-Di-O-Benzyl-1-benzylinosine (14). To a solution of NaH (980 mg, 40 mmol) in Me_2SO (20 mL) was added, under argon, a solution of **12** (6.0 g, 13.6 mmol) in dry Me_2SO (50 mL). The mixture was stirred for 30 min and benzyl chloride (4.6 mL) was added dropwise. After 4 h, the mixture was poured into ice-water (400 mL), and the product was extracted into Et_2O (4 x 200 mL). The ether extracts were combined, dried (Na_2SO_4), and concentrated in vacuo. The residue was dissolved in MeOH (50 mL) containing TsOH (2.2 g, 13 mmol), and the mixture was stirred overnight at room temperature. The mixture was neutralized (NH_4OH), and then concentrated in vacuo. The residue was chromatographed on silica gel ($\text{CHCl}_3/\text{MeOH}$, 4:1 v/v) to give **14** (4.68 g, 64%) as a foam. ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.56–3.66 (2H, m, $\text{H}5',5''$), 4.09–4.29 (2H, m, $\text{H}3',4'$), 4.51 (2H, s, CH_2Ph), 4.64–4.83 (3H, m, $\text{H}2'$, CH_2Ph), 5.23 (2H, s, CH_2Ph), 5.70 (1H, d, 3-OH), 5.93 (1H, d, $\text{H}1'$, $J_{1',2'} = 5.2$ Hz), 7.29–7.34 (15H, m, CH_2Ph), 8.25,

8.59 (two 1H singlets for H2 and H8). Anal. Calcd for $C_{31}H_{30}N_4O_5$: C, 69.13; H, 5.61; N, 10.40. Found: C, 69.33; H, 5.82; N, 10.21.

3',5'-Di-O-benzyl-2'-O-triflyl-1-benzylinosine (15). To a mixture of **14** (538 mg, 1 mmol), DMAP (122 mg, 1 mmol) and Et_3N (202 mg, 2 mmol) in CH_2Cl_2 (15 mL) was added CF_3SO_2Cl (336 mg, 2 mmol). The mixture was stirred for 15 minutes, and then concentrated in vacuo. The residue was chromatographed on silica gel ($CHCl_3/Me_2CO$, 20:1 v/v) to give **15** (630 mg, 94%) as a foam. 1H NMR (Me_2SO-d_6) δ 3.58 (1H, dd, H5', $J_{4',5'} = 4.4$, $J_{5',5''} = 12.0$ Hz), 3.70 (1H, dd, H5'', $J_{4',5''} = 4.0$, $J_{5',5''} = 12.0$ Hz), 4.28-4.44 (1H, m, H4'), 4.44 (2H, s, CH_2Ph), 4.64 (2H, s, CH_2Ph), 4.64-4.77 (1H, m, H3'), 5.23 (2H, s, CH_2Ph), 6.08-6.16 (1H, m, H2'), 6.45 (1H, d, H1', $J_{1,2'} = 2.5$ Hz), 7.26-7.33 (15H, m, CH_2Ph), 8.23, 8.61 (two 1H singlets for H2, H8). This compound decomposed prior to elemental analyses.

Reaction of 15 with TASF. Synthesis of 3',5'-Di-O-benzyl-2'-deoxy-2',3'-didehydro-1-benzylinosine (16). A solution of **15** (670 mg, 1 mmol) in dry CH_2Cl_2 (10 mL) was cooled to $-70^\circ C$ in a dry ice/acetone bath. To this solution was added a solution of TASF (900 mg, 3 mmol) in CH_2Cl_2 (6 mL) under argon. The mixture was allowed to warm to room temperature, and stirring was continued for 24 h. An additional amount of TASF (900 mg in 6 mL of CH_2Cl_2) was added, and the stirring continued for 24 h. The reaction was quenched by addition of satd $NaHCO_3$ (10 mL). The organic layer was separated, washed with H_2O (5 mL), dried ($MgSO_4$), and concentrated to dryness in vacuo. The residue chromatographed on silica gel ($CHCl_3/Me_2CO$, 20:1 v/v). **3-Benzyloxy-2-benzyloxymethylfuran (17)** (47 mg, 16%) was eluted first from the column followed by **16** (320 mg, 62%).

Compound **17** was obtained as a foam. 1H NMR (Me_2SO-d_6) δ 4.39 (2H, s, CH_2Ph), 4.40 (2H, s, CH_2Ph), 5.03 (2H, s, CH_2OCH_2Ph), 6.60 (1H, d, H4, $J_{4,5} = 2.2$ Hz), 7.29 (5H, s, CH_2Ph), 7.36 (5H, s, CH_2Ph), 7.49 (1H, d, H5). Anal. Calcd for $C_{19}H_{18}O_3$: C, 77.53; H, 6.16. Found: C, 77.28; H, 6.37.

Compound **16** was also obtained as a foam. 1H NMR (Me_2SO-d_6) δ 3.58-3.63 (2H, m, H5',5''), 4.44 (2H, s, CH_2Ph), 4.83 (1H, m, H4'), 5.11 (2H, s, CH_2Ph), 5.20 (1H, s, H1'), 5.24 (2H, s, H1', CH_2Ph), 6.87 (1H, s, H2'), 7.21, 7.32, 7.39 (each 5H singlets for CH_2Ph), 8.06, 8.62 (two 1H singlets for H2, H8). Anal. Calcd for $C_{31}H_{28}N_4O_4$: C, 71.94; H, 5.45; N, 10.24. Found: C, 71.67; H, 5.50; N, 10.27.

5'-O-Trityl-1-benzylinosine (18c). A mixture of **4c** (3.58 g, 10 mmol) and TrCl (3.3 g, 12 mmol) in pyridine (50 mL) was stirred at room temperature. An additional amount of TrCl (3.3 g, each) was added on the 2nd and 3rd day, and stirring was continued until all the starting material was consumed. The mixture was concentrated in vacuo, and traces of pyridine were removed by coevaporations with toluene and EtOH. The residue was chromatographed on silica gel (CHCl₃/EtOH, 19:1 v/v) to give **18c** which was crystallized from EtOH (5.40 g, 90%), mp 208–209 °C. ¹H NMR (Me₂SO-d₆) δ 3.20–3.24 (2H, m, H5',5''), 4.10–4.29 (2H, m, H3',4'), 4.61–4.67 (1H, m, H2', collapsed to dd upon addition of D₂O, J_{2',3'} = 5.0, J_{1',2'} = 5.6 Hz), 5.21–5.27 (3H, m, CH₂Ph, OH, became s at 5.24 upon addition of D₂O), 5.57 (1H, d, OH), 5.92 (1H, d, H1', J_{1',2'} = 5.6 Hz), 7.06–7.32 (20H, m, Tr, CH₂Ph), 8.23, 8.51 (two 1H singlets for H2, H8). Anal. Calcd for C₃₆H₃₂N₄O₅: C, 71.98; H, 5.37; N, 9.33. Found: C, 71.86; H, 5.44; N, 9.18.

3'-O-Acetyl-2'-O-triflyl-5'-O-trityl-adenosine (20a). A mixture of 5'-O-trityl-adenosine¹² (497 mg, 1 mmol) and Bu₂SnO²⁰ (249 mg, 1 mmol) in MeOH (50 mL) was heated under reflux until a clear solution was obtained (45 minutes). The solution was concentrated in vacuo, and the residue dissolved in DMF (20 mL). The solution was cooled in an ice bath, and CF₃SO₂Cl (190 mg, 1.1 mmol) was added. After being stirred for 1.5 h at room temperature, the solution was concentrated in vacuo, the residue was dissolved in pyridine (20 mL) and then treated with Ac₂O (1.5 mL). The mixture was stirred for 3 h, and evaporated to dryness in vacuo. The residue was chromatographed on silica gel (CHCl₃/EtOH, 33:1 v/v) to obtain **20a** (208 mg, 31%) as a foam. ¹H NMR (Me₂SO-d₆) δ 2.12 (3H, s, Ac), 3.36–3.49 (2H, m, H5',5''), 4.36–4.40 (1H, m, H4'), 5.90–5.95 (1H, m, H3'), 6.45–6.54 (2H, m, H1',2'), 7.20–7.57 (17H, m, Tr, NH₂), 8.06, 8.35 (two 1H singlets for H2, H8). Anal. Calcd for C₃₂H₂₈F₃N₅O₇S: C, 56.22; H, 4.13; N, 10.24. Found: C, 56.08; H, 4.30; N, 10.11.

In a similar manner, 5'-O-trityl-inosine¹³ (740 mg, 1.45 mmol) was converted into **3'-O-acetyl-2'-O-triflyl-5'-O-trityl-inosine (20b)** (foam, 445 mg, 45%). The eluent used for chromatography was CHCl₃/EtOH (19:1 v/v). ¹H NMR (Me₂SO-d₆) δ 2.11 (3H, s, Ac), 3.30–3.35 (2H, m, H5',5''), 4.38–4.43 (1H, m, H4'), 5.99 (1H, t, H3', J_{2',3'} = J_{3',4'} = 5.7 Hz), 6.32 (1H, dd, H2', J_{1',2'} = 4.1, J_{2',3'} = 5.7 Hz), 6.55 (1H, d, H1', J_{1',2'} = 4.1 Hz),

7.15-7.37 (15H, m, Tr), 8.15, 8.37 (two 1H singlets for H2, H8). Anal. Calcd for $C_{32}H_{27}F_3N_4O_8S$: C, 56.17; H, 3.98; N, 8.19. Found: C, 55.98; H, 4.05; N, 8.07.

Likewise, 3'-O-acetyl-2'-O-triflyl-5'-O-trityl-1-benzylinosine (20c) was obtained from 18c (700 mg, 1.16 mmol) as a foam (580 mg, 64%), using CH_2Cl_2 /EtOAc (16:1 followed by 8:1 v/v) as the eluents for column chromatography. 1H NMR (Me_2SO-d_6) δ 2.11 (3H, s, Ac), 3.32-3.36 (2H, m, H5', 5''), 4.41-4.45 (1H, m, H4'), 5.24 (2H, s, CH_2Ph), 5.88 (1H, t, H3', $J_{2',3'} = J_{3',4'} = 6.0$ Hz), 6.30 (1H, dd, H2', $J_{1',2'} = 4.1$, $J_{2',3'} = 6.0$ Hz), 6.57 (1H, d, H1', $J_{1',2'} = 4.1$ Hz), 7.18-7.36 (20H, m, Tr, CH_2Ph), 8.34, 8.51 (two 1H singlets for H2 and H8). Anal. Calcd for $C_{39}H_{33}F_3N_4O_8S$: C, 60.46; H, 4.29; N, 7.23. Found: C, 60.39; H, 4.37; N, 7.20.

Treatment of 20 with TASF. a) To a cold solution (-70 °C) of 20a (1.0 g, 1.46 mmol) in dry CH_2Cl_2 (15 mL) was added a solution of TASF (1.2 g, 4.35 mmol) in CH_2Cl_2 (9 mL) under argon. The reaction mixture was allowed to warm to room temperature while being stirred. After 24 h, an additional amount of TASF (1.2 g) in CH_2Cl_2 (9 mL) was added, and the stirring was continued for 24 h. The reaction was quenched by addition of H_2O (15 mL). The organic layer was washed with H_2O (15 mL), dried ($MgSO_4$), and concentrated in vacuo. The residue was chromatographed on silica gel by successive elution with 99:1, 97:3, and 95:5 $CHCl_3$ -EtOH (v/v). 2-Triphenylmethyloxymethyl-3-acetoxymethyl-3-acetoxymethyl-3-hydroxyfuran (23) (220 mg, 37%) was eluted first from the column followed by 2-triphenylmethyloxymethyl-3-hydroxyfuran (24), 9-(3-O-acetyl-2-deoxy-2-fluoro-5-O-trityl-β-D-arabinofuranosyl)adenine (21a), 9-(2,3-di-O-acetyl-5-O-trityl-β-D-arabinofuranosyl)adenine (22a) and adenine.

Compound 23 was crystallized from hexane-Et₂O, mp 79-83 °C. 1H NMR (Me_2SO-d_6) δ 2.17 (3H, s, Ac), 3.89 (2H, s, CH_2OTr), 6.55 (1H, d, H4, $J_{4,5} = 2.2$ Hz), 7.25-7.43 (15H, m, Tr), 7.63 (1H, d, H1, $J_{1,2} = 2.2$ Hz). Anal. Calcd for $C_{26}H_{22}O_4$: C, 78.37; H, 5.57. Found: C, 78.40; H, 5.60.

Compound 24 was obtained as crystals (80 mg, 15%), mp 119-120 °C (hexane-Et₂O). The 1H NMR spectrum was identical with that reported.²² Upon acetylation of 24 (45 mg) with Ac₂O (45 μ L) in pyridine (1 mL), 23 (50 mg) was obtained.

Compound 21a was isolated as a foam (33 mg, 4%). 1H NMR (Me_2SO-d_6) δ 2.10 (3H, s, Ac), 3.38-3.40 (2H, m, H5', 5''), 4.20-4.24 (1H, m, H4'), 5.36

(1H, dm, H3', $J_{3',F} = 17.1$ Hz), 5.57 (1H, dm, H2', $J_{2',F} = 51.3$ Hz), 6.49 (1H, dd, H1', $J_{1',2'} = 3.8$, $J_{1',F} = 17.0$ Hz), 7.25–7.36 (15H, m, Tr), 8.07 (1H, d, H8, $J_{8,F} = 2.5$ Hz), 8.15 (1H, s, H2). ^{19}F NMR ($\text{Me}_2\text{SO}-d_6$) δ -189.5 (dt, $J_{1',F} = J_{3',F} = 17.1$, $J_{2',F} = 51.3$ Hz). Anal. Calcd for $\text{C}_{31}\text{H}_{28}\text{FN}_5\text{O}_4$: C, 67.26; H, 5.10; N, 12.65. Found: C, 67.30; H, 5.21; N, 12.50.

Compound **22a** was obtained as a foam, (104 mg, 12%). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.67 (3H, s, Ac), 2.08 (3H, s, Ac), 3.38–3.54 (2H, m, H5', 5''), 4.32 (1H, m, H4'), 5.50–5.75 (2H, m, H2', 3'), 6.65 (1H, d, H1', $J_{1',2'} = 5.5$ Hz), 7.23–7.34 (15H, m, Tr), 8.37 and 8.52 (each 1H, s, H2 and H8). Anal. Calcd for $\text{C}_{33}\text{H}_{31}\text{N}_5\text{O}_6$: Calcd: C, 66.77; H, 5.26; N, 11.79. Found: C, 66.59; H, 5.35; N, 11.54.

b) Compound **20b** (1.0 g, 1.46 mmol) was treated with TASf (2 x 3.0 g) and the products purified as above to obtain **23** (310 mg, 52%), **24** (93 mg, 17%), hypoxanthine (156 mg, 77%), and a mixture of **21b** and **22b** (12 mg).

c) Similar treatment of **20c** (1.0 g, 1.29 mmol) with TASf (2 x 1.06 g) afforded the following compounds, which were separated on silica gel ($\text{CH}_2\text{Cl}_2/\text{EtOAc}$, 9:1 v/v): **23** (133 mg, 26%), **24** (27 mg, 6%), **21c** (83 mg, 10%, foam): ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 2.09 (3H, s, Ac), 3.21–3.33 (2H, m, H5', 5''), 4.20–4.25 (1H, m, H4'), 5.25 (2H, m, CH_2Ph), 5.52 (1H, dm, H3', $J_{3',F} = 15.3$ Hz), 5.54 (1H, dm, H2', $J_{2',F} = 51.0$ Hz), 6.48 (1H, dd, H1', $J_{1',2'} = 4.1$, $J_{1',F} = 17.1$ Hz), 7.23–7.33 (20H, m, Tr, CH_2Ph), 8.05 (1H, d, H8, $J_{8,F} = 2.5$ Hz), 8.62 (1H, s, H2). ^{19}F NMR ($\text{Me}_2\text{SO}-d_6$) δ -197.6 (sextet). Anal. Calcd for $\text{C}_{38}\text{H}_{33}\text{FN}_4\text{O}_5$: C, 70.79; H, 5.16; N, 8.69. Found: C, 70.60; H, 5.23; N, 8.52. Compound **22c** (53 mg, 6%), mp 163–165 °C (AcOEt–hexane). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.69 (3H, s, Ac), 2.06 (3H, s, Ac), 3.34–3.37 (2H, m, H5', 5''), 4.44–4.46 (1H, m, H4'), 5.22 (2H, s, CH_2Ph), 5.45–5.62 (2H, m, H2', 3'), 6.50 (1H, d, H1', $J_{1',2'} = 5.2$ Hz), 7.22–7.33 (20H, m, Tr, CH_2Ph), 8.01, 8.54 (two 1H singlets, H2, H8). Anal. Calcd for $\text{C}_{40}\text{H}_{36}\text{N}_4\text{O}_7$: C, 70.16; H, 5.30; N, 8.18. Found: C, 70.01; H, 5.41; N, 8.18. 1-Benzylhypoxanthine (205 mg, 71%), mp 264–268 °C (from EtOH). (lit.²³ mp 268–270 °C). ^1H NMR of this sample was identical with that of an authentic sample.

2',5'-O-Trityl-1-benzylinosine (25) and 3',5'-O-Trityl-1-benzylinosine (26). A mixture of **4c** (50.0 g, 0.14 mol), DMAP (25.3 g, 0.21 mol) and TrCl (97.2 g, 0.35 mol) in pyridine (550 mL) was stirred for 3 d at 70–80 °C. Additional reagents were added at 24 h (58.3 g of TrCl and 10.0 g of

DMAP) and 48 h (39.0 g of TrCl and 6.0 g of DMAP). The hot mixture was filtered, and concentrated in vacuo. Traces of pyridine were removed by coevaporation with toluene (2 x 300 mL). The residue was placed on the top of a silica gel column (10 x 40 cm), which was eluted with hexane/EtOAc (1:1, 4 L), followed by 1:1 hexane/EtOAc containing 3% EtOH. The amount of EtOH was increased gradually up to 30%. Fractions containing **25** and **26** were collected, and this mixture was rechromatographed on silica gel using hexane/CHCl₃/EtOH (20:20:1 v/v/v) followed by hexane/CHCl₃/EtOH (10:20:1 v/v/v). Compound **25** was eluted first (28.0 g, 24%), mp 231–233 °C (hexane–EtOAc). ¹H NMR (Me₂SO-d₆) δ 3.00–3.06 (2H, m, H5', 5''), 3.20–3.24 (1H, m, H4'), 4.05–4.09 (1H, m, H3'), 4.95–5.02 (1H, m, H2'), 5.15–5.22 (1H, m, OH, exchangeable), 5.22 (2H, s, CH₂Ph), 5.96 (1H, d, H1', J_{1,2'} = 6.2 Hz), 7.02–7.64 (35H, m, CH₂Ph, 2 x Tr), 8.08, 8.17 (two 1H singlets, H2, H8). Anal. Calcd for C₅₅H₄₆N₄O₅: C, 78.36; H, 5.50; N, 6.65. Found: C, 78.17; H, 5.36; N, 6.40.

Compound **26** was eluted next (22.0 g, 19%), mp 187–188 °C (CHCl₃–hexane). ¹H NMR (Me₂SO-d₆) δ 2.64–2.68 (2H, m, H5', 5''), 3.09–3.11 (1H, m, H4'), 4.12–4.14 (1H, m, H3'), 4.70–4.77 (1H, d, H2'), 5.25 (2H, s, CH₂Ph), 6.10 (1H, d, H1', J_{1,2'} = 7.2 Hz), 7.19–7.40 (35H, m, CH₂Ph, 2 x Tr), 8.15, 8.42 (two 1H singlets for H2 and H8). Anal. Calcd for C₅₅H₄₆N₄O₅: C, 78.36; H, 5.50; N, 6.65. Found: C, 78.20; H, 5.41; N, 6.52.

2'-O-Triflyl-3',5'-di-O-trityl-1-benzylinosine (27). To a mixture of **26** (2.0 g, 2.4 mmol), DMAP (290 mg, 2.4 mmol) and Et₃N (480 mg, 4.8 mmol) in CH₂Cl₂ (40 mL) was added CF₃SO₂Cl (800 mg, 4.8 mmol), and the solution was stirred at room temperature for 1 h. The mixture was concentrated in vacuo, and the residue was chromatographed on silica gel (CCl₄/EtOAc, 5:1 v/v) to obtain **27** (1.82 g, 78%) as a foam. ¹H NMR (Me₂SO-d₆) δ 2.92–2.96 (2H, m, H5', 5''), 3.62–3.69 (1H, m, H4'), 4.41–4.43 (1H, m, H3'), 5.23 (2H, s, CH₂Ph), 5.92 (1H, d, H2', J_{1,2'} = 6.3 Hz), 6.58 (1H, d, H-1') 7.18–7.34 (35H, m, CH₂Ph and 2 x Tr), 8.29, 8.32 (two 1H singlets for H2 and H8): (CDCl₃) δ 2.73 (1H, dd, H5', J_{4',5'} = 3.0, J_{5',5''} = 11.1 Hz), 3.22 (1H, dd, H4', J_{4',5'} = 3.0, J_{4',5''} = 1.9 Hz), 3.41 (1H, m, H4'), 4.42 (1H, dd, H3', J_{2',3'} = 4.3, J_{3',4'} = 1.6 Hz), 5.23 (2H, s, CH₂Ph), 5.83 (1H, dd, H2', J_{1,2'} = 7.1, J_{2',3'} = 4.3 Hz), 6.55 (1H, d, H-1'), 7.15–7.40 (30H, m, 2 x Tr), 7.84, 7.99 (two 1H singlets for H2 and H8). This compound was used directly in the next step.

9-(2-Deoxy-2-fluoro-3,5-di-O-trityl- β -D-arabinofuranosyl)-1-benzylhypoxanthine (28). To a solution of **27** (3.24 g, 3.32 mmol) in dry CH_2Cl_2 (40 mL) was added a solution of TASF (2.75 g, 10 mmol) in CH_2Cl_2 (20 mL) at -70°C in an argon atmosphere. The reaction mixture was allowed to warm to room temperature, and stirring was continued for 4 days. An additional amount of TASF in CH_2Cl_2 (5.0 g in 40 mL) was added at -40°C on the 2nd and 3rd day. The reaction was quenched with H_2O (50 mL), the organic layer was separated, washed (H_2O , 2 x 75 mL), dried (MgSO_4), and concentrated in vacuo. The residue was chromatographed on silica gel with hexane/EtOAc (4:1), followed by hexane/EtOAc (2:1) to give **28** (842 mg, 30%) as a foam from CHCl_3 . ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.00–3.02 (2H, m, H5', 5''), 4.27 (1H, d, H3', $J_{3',F} = 19.0$ Hz), 4.38 (1H, s, H4'), 4.44 (1H, dd, H2', $J_{2',F} = 48.3$, $J_{1',F} = 3.0$ Hz), 5.24 (2H, s, CH_2Ph), 6.37 (1H, dd, H1', $J_{1',2'} = 3.0$, $J_{1',F} = 22.0$ Hz), 7.27–7.32 (35H, m, CH_2Ph , 2 x Tr), 7.72 (1H, d, H8, $J_{8,F} = 2.2$ Hz), 8.56 (1H, s, H2). Anal. Calcd for $\text{C}_{55}\text{H}_{45}\text{FN}_4\text{O}_4 \cdot 1/5\text{CHCl}_3$: C, 76.31; H, 5.24; N, 6.45. Found: C, 76.45; H, 5.54; N, 6.23. A small amount of CHCl_3 was detected in the ^1H NMR spectrum of this sample at 8.31.

9-(2-Deoxy-2-fluoro- β -D-arabinofuranosyl)-1-benzylhypoxanthine (29). To a solution of TFA (63.1 mL) in CHCl_3 (670 mL) was added a solution of **28** (6.63 g, 7.85 mmol) in CHCl_3 (30 mL) under argon at -25°C . The mixture was allowed to warm to room temperature, and stirring was continued for 1 h. The mixture was then recooled to -25°C , and EtOH (73 mL) was added. The colorless mixture was concentrated in vacuo, and the residue was triturated with hexane/ Et_2O (1:1 v/v) (2 x 400 mL). The solid residue was collected, and chromatographed on silica gel ($\text{CHCl}_3/\text{EtOH}$, 8:1 v/v) to give **29** (2.5 g, 88%) as colorless foam. ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.68–3.92 (3H, m, H4', 5', 5''), 4.44 (1H, ddd, H3', $J_{2',3'} = 4.4$, $J_{3',4'} = 4.9$, $J_{3',F} = 18.9$ Hz), 5.23 (1H, ddd, H2', $J_{1',2'} = 4.7$, $J_{2',3'} = 4.4$, $J_{2',F} = 53.7$ Hz), 6.39 (1H, dd, H1', $J_{1',2'} = 4.7$, $J_{1',F} = 13.5$ Hz), 7.33 (5H, s, CH_2Ph), 8.26 (1H, d, H8, $J_{8,F} = 1.9$ Hz), 8.62 (1H, s, H2). Anal. Calcd for $\text{C}_{17}\text{H}_{17}\text{FN}_4\text{O}_4$: C, 56.66; H, 4.75; N, 15.55. Found: C, 56.68; H, 4.83; N, 15.61.

9-(2-Deoxy-2-fluoro- β -D-arabinofuranosyl)hypoxanthine (1, F-ara-H). To a solution of **29** (2.0 g, 5.55 mmol) in MeOH (70 mL) was added $\text{Pd}(\text{OH})_2/\text{C}^{24}$ (700 mg), and the mixture was shaken in a Parr hydrogenation apparatus (50 psi). An additional amount of the catalyst (700 mg) was added on the 2nd,

3rd and 6th day. The reduction required 7 days for completion. The catalyst was removed by filtration, the filtrate was concentrated in vacuo, and the residue was acetylated with Ac_2O (1.7 mL) in pyridine (10 mL) for 4 h. The mixture was concentrated, traces of pyridine were removed by coevaporation with EtOH and toluene, and the residue was dissolved in CHCl_3 . The CHCl_3 solution was washed (H_2O , 3 x 20 mL), dried (MgSO_4), and concentrated. The residue was crystallized from CHCl_3 -Et $_2\text{O}$ to give 9-(3,5-di-O-acetyl-2-deoxy-2-fluoro- β -D-arabinofuranosyl)hypoxanthine (1.9 g, 91%), mp 190–191 °C. ^1H NMR (CDCl_3) δ 2.13 (3H, s, Ac), 2.19 (3H, s, Ac), 4.29–4.48 (3H, m, H_4' , H_5' , H_5''), 5.16 (1H, dd, H_2' , $J_{2',3'} = 0$, $J_{1',2'} = 2.7$, $J_{2',F} = 52.4$ Hz), 5.37 (1H, d, H_3' , $J_{3',F} = 15.1$ Hz), 6.45 (1H, dd, H_1' , $J_{1',2'} = 2.7$, $J_{1',F} = 21.7$ Hz), 8.08 (1H, d, H_8 , $J_{8,F} = 2.7$ Hz), 8.31 (1H, s, H_2).

The above acetylated derivative (1.75 g, 6.47 mmol) was treated with a solution of Et_3N (4.03 g, 40 mmol) in MeOH (45 mL) at room temperature for 2 days, and then at 55 °C for 24 h. The mixture was concentrated in vacuo, and the residue crystallized from $\text{Me}_2\text{CO}/\text{MeCN}$ to obtain 1 (1.28 g, 96%), mp 206–208 °C (lit.² amorphous). The ^1H NMR spectrum of this sample was identical with that of an authentic sample.²

Acknowledgment

This investigation was supported by grants from the National Cancer Institute, National Institutes of Health, U.S.D.H.H.S. (Grant Nos. CA-08748 and CA-18601).

References and Footnotes

1. Nucleosides. 157. Relevant papers in this series: Pankiewicz, K. W.; Watanabe, K. A. *Chem. Pharm. Bull.*, **1987**, *35*, 4494, 4498, and also ref.7.
2. Chu, C. K.; Matulic-Adamic, J.; Huang, J.-T.; Chou, T.-C.; Burchenal, J. H.; Fox, J. J.; Watanabe, K. A. *Chem. Pharm. Bull.*, **1989**, *37*, 336.
3. Rainey, P.; Nolan, P. A.; Townsend, L. B.; Robins, R. K.; Fox, J. J.; Santi, D. V. *Pharm. Res., J. Pharm. Soc.*, **1985**, 195.
4. Montgomery, J. A.; Shortnacy, A. T.; Carson, J. A.; Secrist, J. A. *J. Med. Chem.*, **1986**, *29*, 2389.
5. Priebe, T.; Kandil, O.; Nakic, M.; Fang Pang, B.; Nelson, J. A. *Cancer Res.*, **1988**, *48*, 4799.
6. Reichman, U.; Watanabe, K. A.; Fox, J. J. *Carbohydr. Res.*, **1975**, *42*, 233.

7. Pankiewicz, K. W.; Nawrot, B.; Gadler, H.; Price, R. W.; Watanabe, K. A. J. Med. Chem., **1987**, 30, 2314.
8. Ranganathan, R.; Larwood, D. Tetrahedron Lett., **1978**, 4341.
9. Uesugi, S.; Niki, H.; Ikehara, M.; Iwahashi, H.; Kyogoku, Y. Tetrahedron Lett., **1979**, 4073.
10. Cook, A. F.; Moffatt, J. G. J. Am. Chem. Soc., **1967**, 89, 2697.
11. Thiem, J.; Rasch, D. Nucleosides Nucleotides, **1985**, 4, 487.
12. Smith, M.; Rammler, D. H.; Goldbery, I. H.; Khorana, H. G. J. Am. Chem. Soc., **1962**, 84, 430.
13. Hampton, A.; Nichol, L. W. Biochemistry, **1966**, 5, 2076.
14. Herdewijn, P.; Pauwels, R.; Baba, M.; De Clerq, E. J. Med. Chem., **1987**, 30, 2131.
15. Su, T-L.; Klein, R. S.; Fox, J. J. J. Org. Chem., **1981**, 46, 1790.
16. Karpiesiuk, W.; Banaszek, A.; Zamojski, A. Carbohydr. Res., **1989**, 186, 156.
17. MacCoss, M.; Cameron, D. J. Carbohydr. Res., **1978**, 60, 206.
18. This compound was prepared by a modified procedure of Szarek, W. A.; Pinto, B. M.; Iwakawa, M. Can. J. Chem., **1985**, 63, 2149.
19. Robins, M. J.; Wilson, J. S.; Hansske, F. J. Am. Chem. Soc., **1983**, 105, 4059.
20. Selective 2' or 3'-O-acylation using Bu_3SnO was first reported by Wagner, D.; Verheyden, J. P. H.; Moffatt, J. G. J. Org. Chem., **1974**, 39, 24.
21. Alexander, J. U.S. Patent 4,495,180 (Jan. 22, 1985).
22. Compound **24** has been reported as an oil. Binkley, R. W.; Hehman, D. C.; Binkley, W. W. J. Org. Chem., **1978**, 43, 2573; Hansske, F.; Madej, D.; Robins, M. J. Tetrahedron, **1984**, 40, 125.
23. Shaw, E. J. Am. Chem. Soc., **1958**, 80, 3899.
24. Attempted debenzylation of **29** with Pd/C or Pd/BaSO₄ was not successful.

Received August 7, 1990.